- Home
- BH vs CELC Comparison
BH vs CELC Comparison
Compare BH & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BH
- CELC
- Stock Information
- Founded
- BH 1934
- CELC 2011
- Country
- BH United States
- CELC United States
- Employees
- BH N/A
- CELC 55
- Industry
- BH Restaurants
- CELC Medical Specialities
- Sector
- BH Consumer Discretionary
- CELC Health Care
- Exchange
- BH Nasdaq
- CELC Nasdaq
- Market Cap
- BH 561.5M
- CELC 489.7M
- IPO Year
- BH N/A
- CELC 2017
- Fundamental
- Price
- BH $207.89
- CELC $13.19
- Analyst Decision
- BH
- CELC Strong Buy
- Analyst Count
- BH 0
- CELC 6
- Target Price
- BH N/A
- CELC $29.17
- AVG Volume (30 Days)
- BH 6.7K
- CELC 283.3K
- Earning Date
- BH 11-08-2024
- CELC 11-14-2024
- Dividend Yield
- BH N/A
- CELC N/A
- EPS Growth
- BH 158.68
- CELC N/A
- EPS
- BH 180.85
- CELC N/A
- Revenue
- BH $361,664,000.00
- CELC N/A
- Revenue This Year
- BH N/A
- CELC N/A
- Revenue Next Year
- BH N/A
- CELC N/A
- P/E Ratio
- BH $12.76
- CELC N/A
- Revenue Growth
- BH N/A
- CELC N/A
- 52 Week Low
- BH $143.40
- CELC $11.51
- 52 Week High
- BH $219.00
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- BH 72.33
- CELC 37.29
- Support Level
- BH $200.01
- CELC $12.08
- Resistance Level
- BH $213.95
- CELC $16.14
- Average True Range (ATR)
- BH 9.83
- CELC 0.93
- MACD
- BH 2.27
- CELC -0.25
- Stochastic Oscillator
- BH 83.73
- CELC 33.38
About BH Biglari Holdings Inc. Class B
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations, and Maxim. The majority of revenue is derived from the Restaurant Operations segment. The Restaurant Operations segment includes Steak n Shake and Western Sizzlin Restaurant businesses.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.